Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ceralifimod

Merck KGaA shakes up pharma leadership

Stefan Oschmann becomes deputy CEO as Belén Garijo assumes more responsibility

- PMLiVE

Merck Serono pulls development of lung cancer prospect

Ditches tecemotide immunotherapy to focus on anti-PD1

- PMLiVE

Teva supports launch of MS help website

Pow Health aims to help patients in Ireland with long term illnesses

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

Genzyme continues MS drug rollout across EU

Lemtrada and Aubagio now available in Republic of Ireland

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

Biogen Idec building

FDA approves Biogen Idec’s long-acting MS therapy

Plegridy gets US nod just weeks after EU approval

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

MS market set to grow 4% annually

Predictedto reach $20bn by 2023 partly due to Plegridy and ocrelizumab launches

Biogen Idec building

Plegridy approval underlines Biogen Idec’s dominance in MS

And Tecfidera boosts pharma company’s second quarter financial results

- PMLiVE

MS sailing challenge comes to UK

Oceans of Hope yacht has crew of people with multiple sclerosis and is supported by Biogen Idec

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links